HIV Cure Has Long Way to Go Before the Clinic

Get customized medical news and FREE CME!Select Specialties and Topics of Interest to Customize Your NewsContinue to RegisterRegister for FREE customized news, conference, policy and practice coverage and CME tracking. Register Today

Earn Free CME Credits by reading the latest medical news in your specialty.

Sign Up

Published: Jul 1, 2013

KUALA LUMPUR -- The science of an HIV cure is in its infancy but scattered cases of remission -- so-called "functional" cures -- give hope that it is possible, experts said here.

But if the tempo of development is similar to that of anti-HIV drugs in the late 1980s and early 1990s, a useful strategy is still some years away, according to Steven Deeks, MD, of the University of California San Francisco.

"I think we're in 1987," Deeks told MedPage Today -- a period when no drugs were yet available and researchers were just learning such basic things as how to measure HIV in blood and what viral targets for drugs existed.

It would take another 8 or 9 years before the first triple-drug cocktails were proved to stop HIV replication and stave off AIDS.

Similar basic questions now preoccupy scientists trying to find a cure for HIV, Deeks said here on the eve of the 7th International AIDS Society meeting on HIV pathogenesis, treatment, and prevention.

But how long it will take until a safe, effective cure is available remains an open question, commented Nobel laureate Francoise Barré-Sinoussi, PhD, the AIDS society's president.

The "sporadic cases" of apparent cure and even much of the basic research being presented at the AIDS society meeting and at a separate 2-day pre-conference symposium on curative strategies are "pieces of the puzzle," she told MedPage Today.

The solution of the puzzle may not use all of the pieces being investigated today, Barre-Sinoussi said, but the "knowledge that we are accumulating now" will eventually lead to a cure or remission.

But a cure is the next important step in combating the HIV/AIDS pandemic, Deeks later said in a keynote speech to the conference's opening session, because even well-treated HIV has a series of dangerous consequences, including premature aging, dementia, and cardiovascular disease.

Given the sheer number of people with HIV in the world -- some 34 million according to the Joint United Nations Programme on HIV/AIDS (UNAIDS) -- those consequences have the potential to overwhelm healthcare systems not geared to deal with chronic disease, Deeks told delegates.

Evidence is mounting, he said, that curing HIV infection is possible. Among that evidence:

But, while those cases are encouraging, they remain anecdotal, commented Sharon Lewin, MD, of Monash University in Melbourne, Australia, who was a co-chair, with Deeks, of the cure symposium, which featured many of the same players as the AIDS society meeting.

"Anecdotes never mean much to me," she told MedPage Today, adding she prefers the hard data from clinical trials.

Nonetheless, Lewin said, what much of the evidence seems to be saying is that the reservoir of resting T cells that are infected with HIV must be depleted or destroyed for a cure to have a chance.

Those latently infected T cells, though, are difficult to find -- they are infected in the sense that they contain HIV DNA integrated into their genome, but they only rarely lead to HIV replication.

But if a patient is not on effective antiretroviral therapy and resting cells become active, the result has long been thought to be a resumption of full-blown HIV infection.

That's why the cases of the Mississippi baby and the Visconti cohort are so striking -- they seem to defy that long-held dogma. The problem is that they also seem difficult to apply more generally.

Any cure for HIV will have to meet three characteristics, argued Carl Dieffenbach, PhD, of the National Institute of Allergy and Infectious Diseases in Bethesda, Md.

It must first of all be safe, he said in a closing talk to the cure symposium. Then it must be less difficult for patients than their current anti-HIV drug regimens.

And it must be scalable -- able to be used to treat not hundreds or even thousands of patients, but millions around the world, Dieffenbach said.

North American Correspondent for MedPage Today, is a three-time winner of the Science and Society Journalism Award of the Canadian Science Writers' Association. After working for newspapers in several parts of Canada, he was the science writer for the Toronto Star before becoming a freelancer in 1994. His byline has appeared in New Scientist, Science, the Globe and Mail, United Press International, Toronto Life, Canadian Business, the Toronto Star, Marketing Computers, and many others. He is based in Toronto, and when not transforming dense science into compelling prose he can usually be found sailing.

View the original article here